Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes.
about
Mechanisms responsible for excess weight loss after bariatric surgeryThe gut sensor as regulator of body weight.Gastrointestinal hormones and bariatric surgery-induced weight lossPrebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats.The Improvement of Hyperglycemia after RYGB Surgery in Diabetic Rats Is Related to Elevated Hypothalamus GLP-1 Receptor Expression.Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans.Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.Gut feelings about diabetes.Incretin hormones and the satiation signal.Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease.GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery?Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients.Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery.The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
P2860
Q35529693-3A247791-F178-4E51-B134-121BC079241AQ35535513-D4C0798B-4075-4421-8B72-610D94FAF371Q35581251-0978C2B6-BDA3-4559-BFE1-9833636DDA39Q37092598-CA04E9DB-0D9E-4B09-B233-FC90CA7540EFQ37239652-F4210B97-8DBD-4E13-9A8B-2D26A6B01BAEQ37471710-D1B35F88-F74D-4674-86BF-A1E9A5FA7C45Q37611715-2AEF4F93-2C01-44AD-8743-FDFF1717FB82Q37939367-626B2A45-B66C-497B-B5E4-C2F35D252379Q37990142-BD186509-BEB1-45BA-8496-FEE934E28EFBQ38072203-BF1DED6A-A3C3-477E-B12C-B5D04A672131Q38236210-C5B019AA-5F14-4D6B-B4C0-B904C156D7F7Q38307449-9AB5F3C5-56AE-454E-BE4D-1650DA568525Q46854679-980F01A6-DB3C-4350-8A54-E264DF9F30C6Q48094071-18E20045-B843-474E-BF18-B6E98AEC0265Q48124060-292B604E-C81C-4F78-884F-B7E3B7CF1D1FQ51363916-3CCBBA4F-73BB-404F-AAE3-364758C3B678
P2860
Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Gastric bypass surgery, but no ...... patients with type 2 diabetes.
@en
type
label
Gastric bypass surgery, but no ...... patients with type 2 diabetes.
@en
prefLabel
Gastric bypass surgery, but no ...... patients with type 2 diabetes.
@en
P2093
P2860
P1476
Gastric bypass surgery, but no ...... patients with type 2 diabetes.
@en
P2093
B J Van der Schueren
B Laferrère
J Teixeira
N J Swerdlow
P Gorroochurn
P2860
P304
P356
10.1111/J.1463-1326.2011.01358.X
P577
2011-04-01T00:00:00Z